Summary Interferon (IFN) 
Chronic granulocytic leukaemia (CGL) is a clonal myeloproliferative disease affecting the haemopoietic stem cell. A translocation of the c-abl proto-oncogene from the end of chromosome 9 to the break point cluster region (bcr) of chromosome 22, with the formation of a new gene (abl/bcr), occurs in virtually all patients, although the translocation can be recognised morphologically as the Philadelphia chromosome (Ph') in only 90-95% (Kantarjian et al., 1988) .
Patients present with a myeloid leukocytosis, anaemia, splenomegaly and weight loss. These manifestations are easy to control initially by treatment with busulphan or hydroxyurea. Disease progression becomes evident early in the course of CGL, and is manifested by an increase in the growth rate of the leukaemic population, so that the remissions become shorter and shorter as the leukocyte doubling time decreases with each successive relapse. After passing through an accelerated phase, increasing anaemia and thrombocytopenia develop as the marrow is replaced by myeloid, erythroid, megakaryocytic or lymphoid blast cells. The blast phase of the disease may respond to an altered form of treatment, but the remissions are short and death usually ensues within a year (Bergsagel, 1983) .
None of the treatments devised for CGL (aside from allogeneic or syngeneic marrow transplantations) has altered the course of the disease. Survival is determined by the time required for the disease to progress to the blast phase, and since none of the chemotherapeutic approaches to the treatment of CGL have succeeded in delaying or preventing the onset of the blast phase, there has not been an improvement in survival over that reported by Minot and others for untreated patients (Kantarjian et al., 1988; Bergsagel, 1967; Minot et al., 1924) .
We became interested in testing the effect of interferon on the course of CGL as a result of the demonstration that interferon reduces the self-renewal capacity of myeloblast colony forming cells (Taetle et al., 1980) . Numerous clinical trials have shown that interferon alone can achieve satisfactory haematological remissions in about 70% of patients, with recovery of normal marrow metaphases to more than 65% in about one-third of patients (Kantarjian et al., 1988; Talpaz et al., 1986 Talpaz et al., , 1987 Morra et al., 1987; Niederle et al., 1987; Ozer, 1988) . The Ph' chromosome disappeared from the marrow metaphases in a number of these patients. In this study we have followed the leukocyte doubling time (Ldt) as an index of disease progression. Galton (1959) was the first to report the progressive shortening of the Ldt during relapses from busulphan-induced remissions in CGL patients. Later studies revealed that this progressive increase in the regrowth rate of the leukemic population was a consistent feature of CGL patients, and that there was a good correlation between the Ldt and survival (Bergsagel, 1967) . Thus, the Ldt is a strong prognostic factor in CGL, with the longer doubling-times being associated with better survival.
Materials and methods
To be eligible for this study patients had to be in the chronic phase of chronic granulocytic leukaemia (CGL). The presence of the Ph' chromosome, or bcr rearrangement, was not required for the diagnosis of CGL when this study was started. Patients with more than 10% myeloblasts in the blood or marrow differential, persistent platelet counts of less than 100 x 109 1', and those in whom the leukaemia could not be controlled with busulphan alone, were not entered. Patients were required to sign informed consent forms before entry on study.
The study design is illustrated in Figure 1 . Patients were treated with busulphan, 4-6 mg per day, to bring the leukocyte count below 10 x 1091-'. Busulphan was then stopped, and the leukocyte doubling time (Ldt) Figure 1 . In the relapse labelled 1, the IFN fails to influence the course of the disease, and the Ldt becomes shorter than the control Ldt on no therapy. In the relapse marked 2, the Ldt is slowed, and in 3 a rise in leukocytes above 10 x 109 -' is prevented by IFN maintenance therapy. Thus, each patient acts as their own control, for we compared the Ldt on IFN maintenance therapy with their original Ldt on no therapy. IFN was stopped when the disease progressed to enter the accelerated or blast phase.
Karyotypes of marrow cells were done before and after starting IFN. G-banded chromosome studies were done on direct marrow preparations, and on marrow cells cultured for 24 h in the absence of phytohaemagglutin, by Dr Ian Dube and his associates in the University of Toronto Hospitals Cancer Cytogenetics Laboratory.
Studies of the structure of the leukocyte DNA of cases 4, 5 and 11, using three restriction enzymes (Bam H1, Eco RI and Hind iii) and Southern blot analysis with cDNA probes for the major bcr region (Canaani et al., 1984) , were done by our colleague Dr Mark Minden.
Results
The characteristics of the 14 CGL patients entered in this study are shown in Table I . All these patients were still in the chronic phase of the disease and responsive to busulphan. All had received prior treatment with busulphan because the study design required the determination of the Ldt during a relapse on no therapy from a busulphan-induced remission. The interval from diagnosis to starting IFN ranged from 3 to 60 months, with a median of 14.5 months. The median age was 45 years, with a range of 23-67. There were four females and 10 males.
A typical Ph' chromosome was detected in the chromosome analysis of all patients, except for cases 4 and 5, who had an extra 21 chromosome, and case 11, who had a normal karyotype. Marrow cells or DNA for case 4 were not available for study. The studies of the marrow cell DNA of cases 5 and 11 have shown bcr rearrangement.
The influence of IFN maintenance therapy is illustrated in Figure 2 . There has not been a rise in leukocyte count above 30 x 1091-' in six patients (cases 2, 3, 7, 11, 12 and 13 ). An additional patient case (case 9) had a stable leukocyte count below 10 x 109 1-1 for 8 months, which then began to rise, The dose of IFN required to maintain the leukocyte count below 10 x I09 1' is shown in Table II for the six patients who have not relapsed (cases 2, 3, 7, 11, 12 and 13), and an additional patient who was controlled for 8 months and then relapsed (case 9). The required dose of IFN ranged from 1 x 106 U M-2 three times per week to 5.2 x 106 U M-2 daily, with a median of 2 x 106 UM-2 three times per week.
The delaying effect of IFN therapy on the regrowth rate of the leukaemic population (the Ldt) persisted after IFN therapy was discontinued. This is shown in Table III for all of the patients who have had their Ldt determined before, during and after stopping IFN. It will be noted that the first Ldt after stopping IFN did not become shorter than the preceding Ldt determined while on IFN in any of these patients. In case 14, however, the Ldt during the second relapse after stopping IFN, did shorten to 10 days, a value similar to the Ldt before IFN. Subsequent maintenance IFN therapy has again slowed the relapse LDT in case 14. In this case IFN therapy has delayed progression by at least 21 months.
Cases 5 and 6 have died in blast crisis. Case 4 showed progression of the leukaemia, with shortening of the Ldt, but died from the complications of severe chronic obstructive pulmonary disease, rather than leukaemia.
Marrow transplantation from HLA compatible siblings has been attempted for two patients. The experience with the marrow transplant for case 1 was instructive. This man responded with lengthening of the Ldt to 112 days (compared to a control Ldt of 31 days on no therapy) during the first course of IFN. IFN was started again after a course of busulphan, but the disease could not be controlled and the Ldt shortened to 23 days. A marrow karyotype revealed the development of an additional Ph' chromosome, and other chromosome abnormalities (46, XY, -13, + 22, t(9:22) (q34; qll), 9q-). When busulphan failed to control the relapse the patient was prepared for a marrow transplant with cytosine arabinoside 60 mg intravenously every 8 h for 5 days (15 doses), followed by cyclophosphamide 3,840 mg intravenously on days 6 and 7. Plasmaphoresis was done on days 8, 9 and 10. After total body irradiation of 500 cGy in one fraction on day 11, a transplant of 2.3 x 1010 nucleated marrow cells from a tissue-compatible sister was administered. Cyclosporin A, in a dose of 6.25 mg kg-' by month every 12 h, was started 1 day before the marrow transplant and continued for 6 months. Marrow recovery was prompt with a rise in platelets to 129 x I0'1-' by day The survival of this cohort of patients is shown in Figure  3 , together with the survival of 813 Ph'-positive 'good risk' CGL patients in the chronic phase, treated with conventional The leukocyte count could not be controlled by IFN maintenance therapy in any of the patients with a control Ldt of less than 40 days. This observation suggests that IFN is most effective when it is administered early in the course of CGL, and that it is relatively ineffective once the disease has progressed to the stage that the Ldt has shortened to less than 40 days. Still, IFN did not alter the course of the disease in all patients, for at least 4 have progressed to enter the blast phase of the disease.
The return of normal metaphases to the marrow of a substantial proportion of CGL patients after treatment with IFN has been encouraging (Talpaz et al., 1986 (Talpaz et al., , 1987 Morra et al., 1987; Niederle et al., 1987; Ozer, 1988) . The observation that normal metaphases reappeared in the marrow of 2 of our patients, and that IFN treatment resulted in the disappearance of Ph'-positive cells following marrow transplantation in another adds further support to the view that IFN either selectively inhibits the growth of Ph'-positive cells, or frees normal haemopoietic precursor cells from suppression by a factor produced by the leukaemic cells.
The observations that IFN maintenance therapy has prevented relapse in six patients, has slowed the Ldt in an additional five patients and reduced the proportion of Ph' chromosome positive metaphases, are encouraging. However, IFN therapy has failed to prevent progression of CGL to the blast phase in four patients, and three have entered the accelerated phase. It is too early to judge whether IFN maintenance therapy will delay the onset of the blast phase in some patients, and prolong survival. The design of our study does not allow us to draw any conclusions regarding the influence of IFN maintenance therapy on survival. IFN may have a beneficial effect on only a subset of patients, and the determination of the value of this form of treatment will require large randomised studies, such as the MRC trial of IFN in chronic myeloid leukaemia, and another in the Federal Republic of Germany (Hehlmann et al., 1989) .
